Premier Alternatives

Highlightll Pharma

Hangzhou, China · Founded 2017 · In IPO Registration

Developer of a drug development approach designed to create therapies for autoimmune and inflammatory diseases affecting systemic and central nervous system conditions. Highlightll Pharma is based in Hangzhou, China and was founded in 2017. Its last reported valuation was $346 million in Nov 2025. It has raised $97.3 million.

Last reported valuation
$346.2M
Oct 2026
Priced at
—
Total raised
$97.3M
Last round
—

Highlightll Pharma key facts

as of Oct 2026
  • Developer of a drug development approach designed to create therapies for autoimmune and inflammatory diseases affecting systemic and central nervous system conditions.
  • Highlightll Pharma is valued at approximately $346.2M as of Oct 2026 (last reported valuation).
  • It has raised $97.3M; the latest was IPO in Dec 2025.
  • Notable investors include CICC Capital, Hillhouse Investment Group, Shenzhen Yifeng Investment Management Enterprise, Infinity Group, Hankang Capital — 11 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$346.2M

Highlightll Pharma's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Highlightll Pharma with a free account
  • ·The complete investor list: 11 names
  • ·Watch Highlightll Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Highlightll Pharma funding rounds

No rounds on record

No funding rounds for Highlightll Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Highlightll Pharma valuation

Highlightll Pharma's last reported valuation was $346 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

Highlightll Pharma investors

11 investors are on record for Highlightll Pharma, including CICC Capital, Hillhouse Investment Group, Shenzhen Yifeng Investment Management Enterprise and Infinity Group.

About Highlightll Pharma

Developer of a drug development approach designed to create therapies for autoimmune and inflammatory diseases affecting systemic and central nervous system conditions. The company offers a pipeline focused on neuroinflammation and immune modulation, enabling patients with autoimmune and neurodegenerative conditions such as Alzheimer's and Parkinson's disease to access treatments intended to slow disease progression and improve quality of life.

Sector
Healthcare
HQ
Hangzhou, China
Founded
2017
Employees
100
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.